Clinical Trials

Study : NANT 2004-03

A Phase I study of intravenous fenretinide in pediatric neuroblastoma

Study Chair: Barry J. Maurer, MD PhD

This study seeks to determine the maximal tolerated dose of fenretinde given every 21 days for 6 courses as an intravenous infusion over 5 days in patients with recurrent high-risk neuroblastoma.

If you would like to download or watch a video describing this clinical trial, please click here: N04-03 IV formulation video
The Childrens Hospital Los Angeles, Barry Maurer, M.D., PhD, C. Patrick Reynolds, M.D., PhD., of Childrens Hospital Los Angeles, and the federal government hold patents and/or patent applications on how fenretinide (the study drug) was made into an intravenous emulsion and they may benefit financially from the future use of the study drug.